[Comparison of the acetylcholine receptor antibody titer and clinical course in neonatal myasthenia].
Ten to fifteen percent of infants of myasthenic mothers develop neonatal myasthenia independent of the severity of the maternal disease. The antiacetylcholin receptor-protein antibodytiter (AChR-AK) was followed through the first twelve months in a boy who's mother suffered from myasthenia gravis (M.G.) since twelve years. Only unspecific symptoms for an impaired neuromuscular transmission were found, the diagnosis however was confirmed by determination of AChR-AK (alpha-Bungarotoxin binding assay, Lindström 1979). Maternal AChR-AK did not change during the observation period: values were between 120 X 10(-9)mol/l and 140 X 10(-9)mol/l. The neonatal titer on day one was 100 X 10(-9) mol/l, somewhat below the corresponding maternal titer (120 X 10(-9)mol/l). By 7 months the AchR-AK had decreased to the reference value according to the half time for IgG (t/2 = 17 days). In contrast to Keesey and Donaldson we found no relationship between AChR-AK levels and clinical course.
D000328:Adult; D001238:Asphyxia Neonatorum / Q000276:immunology*; D001323:Autoantibodies / Q000032:analysis*; D002657:Child Development; D004576:Electromyography; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009157:Myasthenia Gravis / Q000235:genetics / Q000276:immunology*; D011247:Pregnancy; D011950:Receptors, Cholinergic / Q000276:immunology*; D012127:Respiratory Distress Syndrome, Newborn / Q000276:immunology; D013036:Spasms, Infantile / Q000276:immunology
D001323:Autoantibodies; D011950:Receptors, Cholinergic
Vergleich von Acetylcholin-Rezeptor-Antiköpertiter und klinischem Verlauf bei "neonataler Myasthenie".